Chemomab Therapeutics Ltd.

Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.

CMMB | NDAQ

Overview

Corporate Details

ISIN(s):: US16385C1045 (+1 more)
LEI:
Country:: United States of America
Address:: KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV
Website:: https://www.chemomab.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's approach is centered on its discovery of the soluble protein CCL24 as a key driver of the vicious cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class, dual-activity monoclonal antibody designed to bind to and neutralize CCL24. Nebokitug has demonstrated disease-modifying potential and a favorable safety profile in multiple clinical trials for severe fibrotic diseases. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial in primary sclerosing cholangitis (PSC), for which nebokitug has received FDA Fast Track and Orphan Drug designations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Daesung Microbiological Labs. Co. Ltd Researches and manufactures veterinary vaccines and medicines for livestock, fish, and canines.	South Korea	036480
DAEWOONG PHARMA A global R&D partner for drug development, manufacturing, and commercialization services.	South Korea	069620
DAIICHI SANKYO COMPANY, LIMITED A global pharmaceutical firm developing novel therapies with a focus on oncology and ADCs.	Japan	4568
Daito Pharmaceutical Co., Ltd. Manufactures APIs, generic drugs, and health foods; provides contract manufacturing services.	Japan	4577
Dare Bioscience, Inc. Advancing innovative therapies for women's health in contraception, fertility, and sexual health.	United States of America	DARE
Day One Biopharmaceuticals, Inc. Developing targeted cancer therapies for all ages, with a focus on pediatric oncology.	United States of America	DAWN
DBV Technologies S.A. Developing non-invasive skin patch immunotherapies for food allergies and immune diseases.	United States of America	DBVT
D&D Pharmatech Inc. Develops oral & injectable peptide therapies for metabolic & chronic diseases like obesity.	South Korea	347850
Dechra Pharmaceuticals PLC Develops & sells veterinary pharmaceuticals for companion animals, exclusively to veterinarians.	United Kingdom	DPH
Denali Therapeutics Inc. Developing therapies for neurodegenerative diseases that cross the blood-brain barrier.	United States of America	DNLI